Bioavailability. The levels of radioactivity shall be de- termined in whole blood, blood plasma or blood serum at 15 and 30 minutes and at 1, 2, 8, 24, 48, and 96 hours after initiation of dosing.
Bioavailability. The levels of ra- dioactivity shall be determined in whole blood, blood plasma or blood serum at 15 minutes, 30 minutes, 1, 2, 3, 6, 9, and 18 hours after dosing; and at 30 minutes, 3, 6, 6.5, 7, 8, 9, 12, and 18 hours after initation of inhalation exposure.
Bioavailability. The levels of test substance and relevant metabolites, as appropriate, shall be determined in whole blood, blood plasma or blood serum at appropriate intervals after initiation of intravenous, dermal, and inhalation exposure. The sampling in- tervals should be compatible with the exposure route under study. The deter- minations need only be done on ani- mals administered the test substance containing 14C-n-hexane or, if the xxx- lytical sensitivity is equal or greater, unlabeled test substance may be used.
